Accession Number:



Identifying New Chemical Entities that Treat and Prevent Relapsing Vivax and Drug Resistant Falciparum Malaria in U.S. Military Personnel

Descriptive Note:

Technical Report,30 Sep 2015,29 Sep 2016

Corporate Author:

The Geneva Foundation Tacoma United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Our project has now nearly completing the screening of 400,000 compounds from the National Center for Advancing Translational Sciences NCATS chemical library, for activity against Plasmodium falciparum asexual blood stages. To date we have nearly 2,000 compounds that inhibit growth at low to submicromolar concentrations Nearly 600 of our prioritized hit compounds have been tested against rodent malaria liver stages and we have a set of 43 active compounds that have promising potency and selectivity from which to initiate in vivo assays to assess for cure and prophylaxis. We have also made progress with generating plasmids to engineer Plasmodium cynomolgi parasites that can be used to screen for activity against liver stages in a model of relapsing malaria. We are on track with our goal to identify chemical series that can be tested as candidate medicines to cure and prevent malaria in US Military personnel.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement: